Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Vaccination

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44400   clinical trials with a EudraCT protocol, of which   7411   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    2,014 result(s) found for: Vaccination. Displaying page 57 of 101.
    «« First « Previous 53  54  55  56  57  58  59  60  61  Next» Last»»
    EudraCT Number: 2015-001545-81 Sponsor Protocol Number: 112269 Start Date*: 2015-06-10
    Sponsor Name:GlaxoSmithKline Biologicals
    Full Title: A Phase IV, double-blind, randomised, placebo-controlled study to evaluate immunogenicity, reactogenicity and safety of GlaxoS-mithKline (GSK) Biologicals’ oral live attenuated HRV vaccine in healt...
    Medical condition: Rotavirus gateroenteritis
    Disease:
    Population Age: Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2011-000092-13 Sponsor Protocol Number: INF-001 Start Date*: 2011-05-16
    Sponsor Name:
    Full Title: A trial aimed at enhancing immunity to Influenza in elderly individuals through reversal of immune senescence mediated by herpes virus infection.
    Medical condition: The trial is aimed to improve the efficiency of the seasonal influenza vaccine. Healthy volunteers who are positive for cytomegalovirus (CMV) will be recruited and given anti-viral treatment. We h...
    Disease:
    Population Age: Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2006-006680-23 Sponsor Protocol Number: 109835 Start Date*: 2007-10-16
    Sponsor Name:GlaxoSmithKline Biologicals
    Full Title: A phase III, open, randomized, controlled study to demonstrate the immunogenicity, reactogenicity and safety of GSK Biologicals meningococcal serogroup ACWY conjugate vaccine (GSK134612, MenACWY-TT...
    Medical condition: One dose primary immunization against Neisseria meningitidis (N. meningitidis) serogroups A, C, W-135, and Y in healthy children aged 12 through 23 months
    Disease:
    Population Age: Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: GR (Completed) DE (Completed) AT (Completed)
    Trial results: View results
    EudraCT Number: 2022-001590-31 Sponsor Protocol Number: 22/01611 Start Date*: 2022-10-20
    Sponsor Name:Norwegian Institute of Public Health
    Full Title: A parallel group, prevention, phase iv, unblinded 2-arm study to investigate hospital admission and deaths due to COVID-19, after receiving an invitation to take a second booster COVID-19 vaccine c...
    Medical condition: COVID-19.
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: NO (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2010-018770-20 Sponsor Protocol Number: DC-005 Start Date*: 2010-05-21
    Sponsor Name:Oslo University Hospital
    Full Title: Phase I/II trial of vaccine therapy in curative resected prostate cancer patients using autologous dendritic cells loaded with mRNA from primary prostate cancer tissue, hTERT and surviving.
    Medical condition: Prostatic cancer patients who have received curative surgery.
    Disease:
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: NO (Completed)
    Trial results: (No results available)
    EudraCT Number: 2021-006960-26 Sponsor Protocol Number: NOR-LAABis-2022 Start Date*: 2022-11-04
    Sponsor Name:Oslo University Hospital - Rikshospitalet
    Full Title: COVID-19 PROPHYLAXIS IN IMMUNOSUPPRESSED PATIENTS WITH NO/POOR SARS-COV-2 VACCINE RESPONSE USING LONG-ACTING ANTIBODIES (AZD7442)
    Medical condition: Kidney transplant recipients with suboptimal immune response to previous SARS-CoV-2 vaccinations
    Disease: Version SOC Term Classification Code Term Level
    20.0 10022117 - Injury, poisoning and procedural complications 10074555 Transplantation complication PT
    21.1 100000004865 10077912 Renal retransplantation LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NO (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2016-004527-23 Sponsor Protocol Number: MM1636 Start Date*: 2017-03-14
    Sponsor Name:Center for Cancer Immune Therapy
    Full Title: Combination therapy with Nivolumab and PD-L1/IDO peptide vaccine with Montanide to patients with metastatic malignant melanoma
    Medical condition: Metastatic malignant melanoma
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10027480 Metastatic malignant melanoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2023-000764-58 Sponsor Protocol Number: 219967 Start Date*: 2023-10-03
    Sponsor Name:GlaxoSmithKline Biologicals SA
    Full Title: A Phase 4, single-arm, open-label, multi-center study to assess the immune response and safety of the meningococcal Group B vaccine MenB+OMV NZ when administered to healthy infants from 2 months of...
    Medical condition: Healthy volunteers (active immunization of infants against invasive meningococcal disease (IMD) due to N. meningitidis serogroup B infection).
    Disease:
    Population Age: Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: (No results available)
    EudraCT Number: 2017-003523-30 Sponsor Protocol Number: 38RC17.191 Start Date*: 2017-12-18
    Sponsor Name:University Hospital Grenoble
    Full Title: Vaccination after hematopoietic stem cell transplantation : a randomized study estimating the interest of an additional injection for patients not reponding at M3.
    Medical condition: Our aim is to determine whether an additional dose of inactivated vaccine can increase the rate of responders among patients who have not responded adequately after 3 injections
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004865 10067859 Allogenic stem cell transplantation LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: FR (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2016-001104-36 Sponsor Protocol Number: IIV-291 Start Date*: 2016-06-01
    Sponsor Name:RIVM
    Full Title: Immunogenicity and safety study of a third measles mumps rubella (MMR-3) vaccine dose in healthy young adults in The Netherlands
    Medical condition: immunological response to an extra mumps immunization (in healthy volunteers)
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: View results
    EudraCT Number: 2021-002014-14 Sponsor Protocol Number: COV-PBO-MO28 Start Date*: 2021-04-20
    Sponsor Name:Fakultní nemocnice Hradec Králové
    Full Title: Antibody and cellular response 28 days after the first dose of COVID-19 vaccine (Moderna) and then 33 weeks after the second dose and 8-12 weeks after the third dose in clinically stable patients w...
    Medical condition: Antibody and cellular response 28 days after the first dose of COVID-19 vaccine (Moderna) and then 33 weeks after the second dose and 8-12 weeks after the third dose in clinically stable patients w...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed)
    Trial results: (No results available)
    EudraCT Number: 2021-003547-24 Sponsor Protocol Number: 21CH134 Start Date*: 2021-08-25
    Sponsor Name:CHU de Saint Etienne
    Full Title: Factors influencing the COVID-19 vaccine immune response (reactogenicity and immunogenicity) according to age and presence or not of a past history of COVID-19. COVIMMUNAGE study
    Medical condition: Volunteer
    Disease: Version SOC Term Classification Code Term Level
    23.1 100000004865 10084465 COVID-19 vaccination LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2021-000333-13 Sponsor Protocol Number: APHP200046 Start Date*: Information not available in EudraCT
    Sponsor Name:APHP DRCI
    Full Title: Efficacy of the nonavalent HPV vaccine in the treatment of difficult-to-treat palmo-plantar warts
    Medical condition: Vaccination by nonavalent vaccine against HPV could lead to a complete resolution of difficult-to-treat palmo-plantar warts in patients of more than 15 years and 3 months of age
    Disease:
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2021-000281-15 Sponsor Protocol Number: mRNA-1273-P204 Start Date*: 2023-09-19
    Sponsor Name:ModernaTX, Inc.
    Full Title: A Phase 2/3, Three-Part, Open-Label, Dose-Escalation, Age De-escalation and Randomized, Observer-Blind, Placebo-Controlled Expansion Study to Evaluate the Safety, Tolerability, Reactogenicity, and ...
    Medical condition: Coronavirus Disease 2019
    Disease:
    Population Age: Infants and toddlers, Children, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2020-000863-22 Sponsor Protocol Number: 150681 Start Date*: 2020-06-23
    Sponsor Name:Thomas Benfield
    Full Title: Safety and immunogenicity following meningococcal and pneumococcal immunization among adult people living with HIV A single center, non-blinded, randomized clinical trial
    Medical condition: Immunogenicity following pneumococcal and meningococcal vaccination among people living with HIV
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004848 10020180 HIV positive LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2022-001615-74 Sponsor Protocol Number: ALXN1820-SCD-201 Start Date*: 2023-05-23
    Sponsor Name:Alexion Pharmaceuticals, Inc
    Full Title: A Phase 2a, Randomized, Open-Label Study to Evaluate Multiple Dosing Regimens of Subcutaneous ALXN1820 in Adult Patients with Sickle Cell Disease
    Medical condition: Sickle Cell Disease (HbSS and HBSß thalassemia).
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2021-003573-58 Sponsor Protocol Number: 2025 Start Date*: 2021-08-09
    Sponsor Name:Antwerp University Hospital
    Full Title: Vaccination against cOvid-19 In CancEr: booster shot BNT161b2 vaccine after full vaccination with ChAdOx1-S vaccine (Tri-VOICE plus)
    Medical condition: Onco-hematological patients
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2020-000657-27 Sponsor Protocol Number: VAC52416BAC1001 Start Date*: 2020-07-10
    Sponsor Name:Janssen Vaccines & Prevention B.V.
    Full Title: A Randomized, Observer-blind, First-in-Human Phase 1/2a Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Three Different Doses of VAC52416 (ExPEC10V) in Adults Aged 60 to 85 Years...
    Medical condition: Healthy volunteers (Prevention of invasive extraintestinal pathogenic Escherichia coli (ExPEC) disease)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Prematurely Ended) BE (Completed) NL (Completed)
    Trial results: View results
    EudraCT Number: 2020-005273-27 Sponsor Protocol Number: VAC52416BAC3001 Start Date*: 2021-09-07
    Sponsor Name:Janssen Vaccines & Prevention B.V
    Full Title: Randomized, Double-Blind, Placebo-controlled, Multicenter Phase 3 Study to Assess the Efficacy, Safety And Immunogenicity of Vaccination With ExPEC9V in the Prevention of Invasive Extraintestinal P...
    Medical condition: Invasive Extraintestinal Pathogenic Escherichia coli Disease
    Disease: Version SOC Term Classification Code Term Level
    21.1 10021881 - Infections and infestations 10052238 Escherichia urinary tract infection PT
    20.0 10021881 - Infections and infestations 10015295 Escherichia infections HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Trial now transitioned) ES (Ongoing) NL (Trial now transitioned) IT (Prematurely Ended) CZ (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2011-000476-34 Sponsor Protocol Number: V59_40 Start Date*: 2011-06-08
    Sponsor Name:NOVARTIS VACCINES AND DIAGNOSTICS S.R.L.
    Full Title: A Phase IV,PlaceboControlled,Randomized Study to Evaluate the Immunogenicity and Safety of a Combined Tetanus, Reduced Diphtheria Toxoid, Acellular Pertussis Vaccine (Tdap, Boostrix) and Quadrivale...
    Medical condition: Menveo is indicated for active immunization of adolescents (from 11 years of age) and adults at risk of exposure to Neisseria meningitidis groups A, C, W135 and Y, to prevent invasive disease.
    Disease: Version SOC Term Classification Code Term Level
    14.1 10021881 - Infections and infestations 10021881 Infections and infestations SOC
    14.1 10021881 - Infections and infestations 10027276 Meningococcal meningitis LLT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    «« First « Previous 53  54  55  56  57  58  59  60  61  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Wed Jun 24 03:09:36 CEST 2026 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA